Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
about
Dopamine release in the basal gangliaThe importance of integrating basic and clinical research toward the development of new therapies for Huntington diseaseStriatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphologyAge-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington diseaseCorticostriatal Dysfunction in Huntington's Disease: The BasicsMouse models of polyglutamine diseases: review and data table. Part IImpaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with CarboplatinReinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolismHuntingtin-associated protein 1 regulates exocytosis, vesicle docking, readily releasable pool size and fusion pore stability in mouse chromaffin cellsSynapsins differentially control dopamine and serotonin releaseDopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouseLocalized drug application and sub-second voltammetric dopamine release measurements in a brain slice perfusion device.Neuropeptide Release is Impaired in a Mouse Model of Fragile X Mental Retardation Syndrome.In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease.Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system.Simultaneous measurement and quantitation of 4-hydroxyphenylacetic acid and dopamine with fast-scan cyclic voltammetry.Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.Dopaminergic Modulation of Striatal Inhibitory Transmission and Long-Term Plasticity.Optimizing the Temporal Resolution of Fast-Scan Cyclic Voltammetry.Quantification of reserve pool dopamine in methionine sulfoxide reductase A null miceBiological sources of inflexibility in brain and behavior with aging and neurodegenerative diseases.Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.Motor function and dopamine release measurements in transgenic Huntington's disease model ratsImpaired dopamine release and uptake in R6/1 Huntington's disease model miceMultiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.Dopamine and glutamate in Huntington's disease: A balancing act.Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.The role of dopamine in Huntington's disease.Dopamine and Huntington's disease.Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Ex Vivo Measurement of Electrically Evoked Dopamine Release in Zebrafish Whole Brain.Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine ModulationRelationship between subthalamic nucleus neuronal activity and electrocorticogram is altered in the R6/2 mouse model of Huntington's disease.
P2860
Q22251247-140F3ADB-7443-4C92-BCBE-1EE5AAB6F5ACQ22306292-95AC31F6-4454-4821-B528-7DFCFF97A09DQ23912227-8DC759AA-12F0-4EAB-AF03-C44089280B8EQ24657764-F78CCC13-41E2-4732-A95E-2EBF25E7FF79Q26738379-B76D248B-FCD1-417E-A2FB-66A3A30D60CCQ26853025-7337B809-C03E-4136-818C-F72E68AA4C9EQ27300384-EB85834C-EA45-4767-AC19-1AF4A7733C9DQ27306293-9FB5354C-0CFA-4E28-AE2F-AE9362272E89Q27309160-3F4CE2B4-F2B6-41C5-AEC9-1234B4AA58A4Q28511792-6E6AF49F-459C-490D-8B9F-1CE0BD0D4A55Q30433690-04C60135-470B-4AEE-9543-7B75DB911D85Q30496436-AB1EAB96-4D3B-42ED-97B4-0238502746DFQ33598679-9F90BD9C-A089-492D-9F98-443762A18F6DQ33863167-F0C3F1B3-D3EB-4DD8-956B-B9C4AA8D9CB1Q34597796-CD873CBE-FCD4-4F10-91E6-242132A01DC0Q35116551-31090B54-E4D2-4808-83AE-6AB4A7D76FB4Q35207525-3D9B8AA9-79B2-44BC-B440-B9973349848BQ35866105-93650AE3-5A5B-4ECD-836E-3356504BC427Q35871006-768BE31F-CD85-40DD-A73F-B134B8018EF6Q35947320-450C802B-9958-4778-9788-DD3FCEEDE914Q36031650-D4292F99-C44D-4A1C-9DAC-91441B019ED0Q36253524-5CA36C47-9063-4051-8994-FD63DD3991E3Q36434965-2C5ACEC7-3614-44BA-804E-2BFF6E6CD169Q36916483-E8B31D18-3E50-46F5-9CCF-A717885D9D70Q36916504-ED1220ED-D45D-4419-97C5-FD8FB8E15D26Q36916526-DC6F8267-ADFD-4C9F-9E6A-F4FD0181F061Q36940345-7427C39B-E8B9-41BC-98C3-47D3696827D3Q36975938-72323ACB-858D-4F70-AF62-2A2771CD2F3CQ37349826-A1A7D300-534E-451B-984B-A1DD29C37A82Q37723743-C99F03FB-9664-4B7B-9845-0F29C126C4AAQ37734563-E8EBB0B6-2E71-4CE7-B92B-9CE1E45BDBCDQ37930190-16B927DC-C7B2-4AF7-8F68-52ED9FC60018Q38121068-1E32F79A-1A16-4058-8043-7B093BFB09FAQ38160307-9CC0A5A3-078F-4835-AD3B-4E9A4CC2F1D7Q38223504-4EDB01E2-2846-4BDD-84E1-29043498D294Q38379277-B1D89F05-0EEE-4023-9CA5-DC5BB2DF09D5Q38603960-A9CE9340-13A0-4AF6-8B0F-5842A980CA82Q38724516-1B7D3065-0DD8-4AE5-90C1-6856DB9350ACQ39041217-480914B4-8CD8-47F8-8E86-E9CF6852CE21Q40963865-0890F897-C7CA-4495-ABEC-CE023BF31B42
P2860
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
@en
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
@nl
type
label
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
@en
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
@nl
prefLabel
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
@en
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
@nl
P2093
P1476
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
@en
P2093
Charles E Miller
Michael A Johnson
R Mark Wightman
Vignesh Rajan
P304
P356
10.1111/J.1471-4159.2006.03762.X
P407
P577
2006-03-29T00:00:00Z